OSX secures Hainan FDA approval for orthopaedic devices
Filed with ASX · · 5 pages · English
Summary by 6ix AI
Osteopore Ltd. has received approval from the Hainan Medical Products Administration for its custom orthopaedic devices, allowing clinical use at a prominent hospital in Hainan, China. This approval serves as a regulatory springboard for the company, facilitating early market access and the generation of real-world data to support future nationwide registration.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Osteopore
- Activities Report March 2026 and Appendix 4C
- Further Drawdown of T2 of the Redeemable Convertible Notes
- Clarification - agreement for injectable regen bone filler
- OSX signs agreement for injectable regenerative bone filler
- OSX secures distribution for autologous dentin bone graft
Later from Osteopore
- Activities Report June 2026 and Appendix 4C
- OSX completes first Hainan custom orthopaedic implant
- Details of Auditor Appointment/Resignation
- OSX strikes orthopaedic deal for 5 Middle East countries
- Half Yearly Report and Accounts
Follow Osteopore into a list and get an email when it puts out news.
Follow Osteopore